Revenue
$2.34M
Fiscal year ended 2026-07-31Operating income
-$71.81K
Fiscal year ended 2026-07-31Free cash flow
$59.50K
Fiscal year ended 2026-07-31Pharma-Bio Serv, Inc. (PBSV) reported revenue of $2.34M and net income of -$14.22K for the fiscal year ended 2026-07-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Pharma-Bio Serv, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Management Consulting Services.
Income
| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.34M | $2.70M | $2.29M | $2.15M | $1.96M | $2.42M | $2.47M | $2.33M | $2.42M | $2.38M |
| Cost of revenue | $1.64M | $1.80M | $1.57M | $1.40M | $1.39M | $1.60M | $1.70M | $1.61M | $1.78M | $1.76M |
| Gross profit | $691.73K | $902.04K | $722.37K | $748.94K | $574.26K | $818.73K | $768.11K | $726.57K | $635.38K | $618.48K |
| Operating income | -$71.81K | $144.68K | -$94.54K | -$133.27K | -$313.88K | -$98.32K | -$92.19K | -$154.13K | -$381.78K | -$313.38K |
| Net income | -$14.22K | $232.99K | $32.86K | -$102 | -$204.25K | $95.35K | $8.54K | $16.11K | -$309.19K | -$213.82K |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 22.91M | shares 22.91M | shares 22.91M | Unavailable | shares 22.94M | shares 22.94M | shares 22.96M | Unavailable | shares 22.96M | shares 22.97M |
| Pretax income | -$11.10K | $239.35K | $36.49K | $4.25K | -$209.03K | $100.86K | $9.65K | -$14.85K | -$290.19K | -$192.64K |
| Income tax expense | $3.12K | $6.37K | $3.63K | $4.36K | -$4.78K | $5.51K | $1.12K | -$30.96K | $19.00K | $21.18K |
| Diluted EPS | $-0.00 | $0.01 | $0.00 | Unavailable | $-0.01 | $0.00 | $0.00 | Unavailable | $0.01 | $-0.01 |
| Selling, general & administrative | $763.55K | $757.36K | $816.91K | $882.21K | $888.14K | $917.05K | $860.30K | $880.70K | $1.02M | $931.85K |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Total assets | $11.44M | $11.50M | $13.55M | $13.65M | $13.59M | $13.90M | $16.08M | $16.29M | $16.32M | $16.92M |
| Current assets | $11.24M | $11.29M | $13.32M | $13.39M | $13.16M | $13.42M | $15.53M | $15.70M | $15.94M | $16.51M |
| Total liabilities | $994.74K | $1.05M | $3.31M | $1.74M | $1.66M | $1.78M | $4.08M | $2.58M | $2.63M | $2.97M |
| Current liabilities | $994.74K | $1.05M | $3.31M | $1.74M | $1.66M | $1.78M | $3.42M | $1.89M | $1.90M | $2.20M |
| Total equity incl. NCI | $10.44M | $10.45M | $10.24M | $11.91M | $11.93M | $12.12M | $12.00M | $13.72M | $13.69M | $13.95M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $2.42M | $2.72M | $2.65M | $2.36M | $2.02M | $2.68M | $2.68M | $2.51M | $2.60M | $2.61M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Cash flow
| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $60.89K | -$365.31K | -$390.14K | $279.67K | $236.52K | -$301.59K | -$429.49K | $78.42K | -$670.33K | -$700.74K |
| Capital expenditures | $1.39K | $2.32K | $2.41K | $350 | $2.04K | $4.26K | $0 | $157.02K | $1.91K | $0 |
| Investing cash flow | -$326.30K | -$1.89M | $2.77M | -$856.66K | $1.63M | -$3.23M | $988.34K | $171.53K | $3.69M | -$458.94K |
| Financing cash flow | $0 | -$1.72M | -$1.68K | -$9.20K | -$5.00K | -$1.74M | $0 | $0 | -$1.75K | -$1.72M |
| Net change in cash | -$273.16K | -$3.97M | $2.38M | -$578.54K | $1.86M | -$5.21M | $539.77K | $247.17K | $3.01M | -$2.90M |
| Stock-based compensation | $8.62K | $8.62K | $8.62K | $4.40K | $10.00K | $10.00K | $10.68K | $3.15K | $14.80K | $14.80K |
| Common dividends paid | $0 | $1.72M | Unavailable | $0 | $0 | $1.72M | Unavailable | $0 | $0 | $1.72M |
| Common share repurchases | $0 | $709 | $1.68K | $9.20K | $5.00K | $17.24K | $0 | $0 | $1.75K | $2.32K |
| Depreciation & amortization | $13.68K | $13.64K | $14.80K | $15.82K | $15.74K | $18.87K | $9.44K | $5.93K | $4.59K | $5.51K |
Derived
| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $59.50K | -$367.63K | -$392.55K | $279.32K | $234.49K | -$305.85K | -$429.49K | -$78.59K | -$672.24K | -$700.74K |
| Gross margin | 29.6% | 33.4% | 31.5% | 34.8% | 29.3% | 33.9% | 31.1% | 31.1% | 26.3% | 26.0% |
| Operating margin | -3.1% | 5.4% | -4.1% | -6.2% | -16.0% | -4.1% | -3.7% | -6.6% | -15.8% | -13.2% |
| FCF margin | 2.5% | -13.6% | -17.1% | 13.0% | 11.9% | -12.7% | -17.4% | -3.4% | -27.8% | -29.5% |
| SBC / revenue | 0.4% | 0.3% | 0.4% | 0.2% | 0.5% | 0.4% | 0.4% | 0.1% | 0.6% | 0.6% |
| Current ratio | 11.30x | 10.80x | 4.03x | 7.70x | 7.93x | 7.54x | 4.54x | 8.32x | 8.39x | 7.52x |
| Revenue YoY growth | 19.0% | 11.8% | -7.1% | -7.9% | -18.8% | 1.7% | 3.8% | -35.2% | -47.2% | -47.9% |
| Net margin | -0.6% | 8.6% | 1.4% | -0.0% | -10.4% | 3.9% | 0.3% | 0.7% | -12.8% | -9.0% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 0.1% | 0.1% | 0.1% | 0.0% | 0.1% | 0.2% | 0.0% | 6.7% | 0.1% | 0.0% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | 2.7% | 9.9% | 102.4% | Unavailable | 5.5% | 11.6% | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PBSV in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-09-14View SEC filing
10-Q · Filed 2026-06-15View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-K · Filed 2026-01-29View SEC filing
10-Q · Filed 2025-09-15View SEC filing
10-Q · Filed 2025-06-16View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.